tbuckley/cabot-search huggingface dataset:
Deaths
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 111: Reduced MK5 Expression Alters Migration, Proliferation, and Collagen Biosynthesis in Murine Ventricular Fibroblasts
Authors: Pramod Sahadevan, Sherin A Nawaito, Angelo Calderone, Matthias Gaestel, Bruce G Allen
Journal: Circulation Research (2017)

MAP kinase-activated protein kinase-5 (MK5), a protein serine/threonine kinase expressed in the heart, has been identified as a substrate for p38α/β and ERK3/4 MAPKs. However, the interacting partners and physiological function of MK5 are just beginning to be understood. This study examined the role of MK5 in murine cardiac ventricular fibroblasts. Confocal immunocytofluorescence microscopy (CIFM) revealed that MK5 immunoreactivity localized primarily to the nucleus whereas ERK3 immunoreactivity was in the cytoplasm. Following serum stimulation, phospho-MK5 immunoreactivity was observed in the cytoplasm and appeared to be associated with the cytoskeleton and pseudopodia. ERK3 immunoreactivity redistributed to membrane ruffles and/or lamellipodia. ERK3 has been reported to be unstable in the absence of MK5: in cardiac fibroblasts, ERK3 immunoreactivity was unaffected by acute knockdown of MK5 with siRNA (MK5-kd), suggesting an as-yet unidentified binding partner may stabilize ERK3 in these cells. MK5 immunoprecipitates from fibroblast lysates contained ERK3 immunoreactivity and proximity ligation assays indicated the presence of ERK3-MK5 complexes in the cytoplasm: these complexes were less abundant in MK5-kd fibroblasts. Cell migration, in response to serum and/or Ang-II was reduced significantly in MK5-kd fibroblasts. In addition, cell proliferation was decreased in fibroblasts isolated from MK5 -/- mice compared to fibroblasts from wild-type litter mate mice (MK5 +/+ ). Surprisingly, both the abundance of type 1 collagen (COL1A1) mRNA and the secretion of soluble COL1A1 were increased in MK5-kd fibroblasts whereas the ability of Ang-II to increase collagen secretion was unaffected. CIFM revealed staining for COL1A1 was diffuse in MK5 +/+ fibroblasts but condensed in the perinuclear region of MK5 -/- cells. A similar pattern of subcellular distribution of COL1A1 immunoreactivity was observed in MK5-kd fibroblasts and was observed in passages 0 through 3. Taken together, these data suggest 1) one or more proteins in addition to MK5 serve to stabilize ERK3 in fibroblasts and 2) MK5 may be involved in cardiac fibroblast proliferation, migration, collagen biosynthesis and, possibly, myocardial remodelling.
Moderated ePoster Session 3
Authors: Y Yeshchenko, Jjj Boyne, ; Spreeuwenberg, Apm Gorgels, G De Weerd, ; Kragten, Hjm Vrijhoef, Ggulmisal Guder, ; Stork, ; Gelbrich, ; Brenner, ; Morbach, ; Berliner, ; Ertl, ; Angermann
Journal: European Journal of Heart Failure (2014)
Hereditary Hemochromatosis
Authors: Tracey A. Rouault
Journal: JAMA (1993)

<h3>SELECTED CASE</h3> A 44-year-old man had shoulder and finger pain and consulted his local physician. Screening blood tests were obtained as part of the initial evaluation and revealed the following values: hemoglobin, 135 g/L; hematocrit, 0.40; serum iron, 37 μmol/L (209 μg/dL); transferrin, 2.19 g/L; transferrin saturation, 95%; and serum ferritin, 2430 μg/L. Liver function tests revealed the following values: aspartate aminotransferase, 43 U/L; alanine aminotranferase, 68 U/L; and alkaline phosphatase and bilirubin, normal. A liver biopsy was performed and examination of tissue sections revealed fatty metamorphosis and an increase in fibrous tissue in portal areas consistent with early cirrhosis. Large amounts of parenchymal iron were noted on Prussian blue staining, particularly in the periportal area. The diagnosis based on the test results was hemochromatosis, and a phlebotomy program was initiated. The patient was referred to the National Institutes of Health where on physical examination the absence of frank arthritis
Leg pain and platelet aggregates in thrombocythemic myeloproliferative disease
Authors: H. H. Salem
Journal: JAMA (1980)

In three patients with thrombocytosis secondary to myeloproliferative disorders, disabling intermittent lower extremity pain occurred in the absence of peripheral vascular insufficiency. In all patients, circulating platelet aggregates were detected. Antiplatelet therapy resulted in prompt relief of pain and the disappearance of platelet aggregates. These findings suggest that abnormal platelet function with the formation of platelet plugs in the microcirculation could be responsible for the observed symptoms and response to treatment. The value of the determination of circulating platelet aggregates in the management of this syndrome is highlighted. (<i>JAMA</i>244:1122-1123, 1980)
Recovery from drug dependence
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In This Issue
Journal: Circulation Research (2011)

Endothelial Activation by Shear Stress (p 410)Fu et al report how two atherosclerosis risk factors synergistically activate one molecular mechanism in vascular endothelial cells.Both disturbed blood flow and high cholesterol are known to promote the formation of atherosclerotic plaques in blood vessels.Previous work by this research team had shown that high cholesterol prompts the endothelial cells lining the blood vessels to increase their surface expression of a molecule called ATPS␤.This molecule binds to ␥/␦ T cells, which are enriched at early-stage atherosclerotic plaques.The team has now discovered that the surface expression of ATPS␤ is increased by disturbed blood flow as well.ATPS␤ is found within the cell associated with mitochondria, as well as at the cell surface, but both disturbed blood flow and high cholesterol promoted the molecule's recruitment to lipid rafts, which translocated it to the membrane.The ␥/␦ T cells recruited by increased ATPS␤ cell surface expression released inflammatory cytokines.These cytokines caused further activation of the endothelial cells, leading to an increase in the proinflammatory cell adhesion molecule-VCAM-1.Since cell surface ATPS␤ expression appears to set off a chain inflammatory reaction, perhaps blocking its translocation might be investigated as a means to slow atherosclerosis.
Correction
Journal: Annals of the Rheumatic Diseases (2015)

Figure 1 Interleukin (IL)-33 expression in temporal arteries of patients with giant cell arteritis (GCA).Representative photomicrographs showing 5-μm-thick paraffin-embedded sections of artery biopsy specimens obtained from controls (A) and patients with GCA (B-F), stained for IL-33.IL-33 expression was observed in inflamed arteries displaying small vessel vasculitis (SVV) (B) and transmural inflammation (C).In SVV IL-33 expression was observed among infiltrating mononuclear cells (arrows) and smooth vascular muscle cells (B).In arteries displaying transmural inflammation IL-33 expression was observed among infiltrating inflammatory mononuclear cells (D) and giant cells scattered through the inflamed wall of inflamed arteries (E).Microvessels distributed through the inflammatory infiltrates also showed intense IL-33 positivity (arrows) (F).(A, original magnification ×100; B-C, original magnification ×250; D-F, original magnification ×400).
MODE OF ACTION OF SOME COMMON LAXATIVES
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Annual Review of Physiology
Authors: R. J. Main
Journal: JAMA (1962)

Among the subjects reviewed by leaders in their fields which are of most interest to physicians are reproduction, physiology of temperature, digestive system, peripheral circulation, heart, cutaneous sensibility, pituitary-adrenal system, memory, nervous system, nerve excitation and synaptic transmission, water and electrolyte metabolism, respiration, and regulation of blood volume. The degree of readability of these essays differs tremendously. Some are merely one sentence abstracts of a tremendous list of references, confirming a quotation by the author of one of the best reviews that "... its orderly classification requires computing machine technics rather than the mind..." Other articles provide brief reviews and summaries which are most helpful to the nonspecialist in the field, such as the chapter on neuroendocrine regulation of blood volume. Many titles are thoroughly inadequate at a time when titles are of increasing importance in indexes of the literature; the editor should have applied the usual requirement of a minimum
Asbestos. An environmental reality
Authors: J. E. Craighead
Journal: JAMA (1984)

Readers of the medical literature doubtless find the asbestos-associated diseases a complex topic. The two reports on this subject in a recent issue ofThe Journaldoubtless contribute to the confusion expressed by many physicians. In the first, Dodson et al<sup>1</sup>record the results of assays of pulmonary tissue from three quite different but relatively small groups of subjects. In contrast to the findings of other investigators,<sup>2-7</sup>these workers failed to detect ferruginous bodies in the lungs of urban residents and rural patients with bronchogenic carcinoma. Several technical considerations and problems of tissue sampling and patient selection could have contributed to the discrepancies between this and earlier reports, but one must ask if the findings are important in the overall context of our understanding of the diseases associated with exposure to asbestos. It is now widely recognized that most of the ferruginous bodies in the lungs of members
The treatment of classical hemophilia with cryoprecipitates. Laboratory control with readily available tests
Authors: P. G. Hattersley
Journal: JAMA (1966)

Four patients with classical hemophilia of various degrees of severity, and with various clinical manifestations, received factor VIII (antihemophilic globulin) concentrates prepared by the cryoprecipitate technique of Pool and Shannon. All four responded well to therapy. One required laparotomy for bleeding peptic ulcer in a Meckel's diverticulum. One developed an inhibitor of factor VIII, but responded well to increased doses of the concentrate. The activated coagulation time (ACT) of whole blood and the activated partial thromboplastin time (PTT), performed on preinfusion and postinfusion blood specimens, served well as monitors of treatment, indicating activity of the material infused and response of the patient.
Reports on Medical &amp; Surgical Practice in the Hospitals
Journal: BMJ (1894)

I IAOSPlITAI.RE i'OlIV.JtNE 2, 1894.quite well aid( eInjoyed a bretakfast.The armn was enorniously swollen, and thle livid patelh apparently ganigrenous.Ile was senit lhomiie in a carriageb about twenty-four lhours after the accident.The swelling very gradually aibated, and, in doing so, passed thlrouglh all the phlases of a bruise.The livid patchl necrosed, and gradually lhealed up.Sandown.
WELL PAID VOLUNTEER SURGEONS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vacation Lectures on Fibrinous Deposition in the Heart: Its History and Practical Meaning
Authors: B. W. Richardson
Journal: BMJ (1860)

Conditions of Disease in which Deposition of Fibrine occurs in the Heart: Symptoms and Diagnosis of Concretion.GENTLEMEN,-From points connected with the structure of fibrinous deposits,and the proofs that these deposits are in many instances laid down prior to death, we pass naturally to consider those conditions of the system which are favourable to deposit-in other words, the diseases in the course of which deposits are formed.To understand clearly the question here involved, we must consider the modifications to which the fibrine of the blood is subjected under various diseased states, and especially those modifications leading to deposit.1.In various conditions the fibrine is, or seems to be, diminished in the blood.These conditions are indicated in dis.eases in which the hemorrhagic tendency prevails.True typhus, and yellow fever, are diseases of this nature.The effects of many poisons, as the cobra poison, the vegeto-alka- loids, the alkalies, and several organic acids, are manifested in this apparent deficiency of fibrine.In these cases, the blood, as Plato would express it, "is no longer under the natural guardianship of its fibres"; so it exudes into the soft struc- tures, giving rise to petechial spot, black vomit, meltena, heema-
Exacerbation of obstructive airway disease by timolol
Authors: F. L. Jones
Journal: JAMA (1980)

<h3>To the Editor.—</h3> The fascinating and scholarly article by Bernadine Z. Paulshock, MD (1980;244:160), on the gynecoid features of Akhnaton, in which she argues that the artisans who created such representations were representing reality, not taking artistic liberties or following formal conventions, accords with an experience my wife and I had several years ago while viewing the ancient Egyptian artifacts of Akhnaton's period. My wife is an ex-marine biologist and ranger-naturalist with the National Park Service and knows a good deal about mammals and birds. Viewing many of these artifacts, she could identify, right down to the species, many of the waterfowl and mammals depicted. Where a species of bird was supposed to have four flight feathers, it had four flight feathers—that kind of accuracy was the rule. I am a veteran sailor and ex-boating magazine writer, and I could recognize, on certain bas reliefs, the masthead knot, bowline, clove
Chromosomal Localization of Putative Tumor-Suppressor Genes in Several Human Cancers
Authors: Jun Yokota, Takashi Sugimura, Masaaki Terada
Journal: Environmental Health Perspectives (1991)

Restriction-fragment-length polymorphism analysis was performed on several different types of human cancers, including carcinoma of the uterine cervix, neuroblastoma, hepatocellular carcinoma, pheochromocytoma, stomach cancer, and small-cell lung carcinoma (SCLC), to determine the chromosomal loci of putative tumor-suppressor genes in each type of tumor because less of heterozygosity (LOH) is supposed to unmask the recessive mutation of tumor-suppressor gene in the remaining allele. Chromosomal loci showing frequent LOH differed among these tumors, suggesting that there are several tumor-suppressor genes in the human genome and that critical genes for the development of each type of tumor are different. In some cases LOH was observed in the early stage of tumor such as chromosome 3p loss in carcinoma of the uterine cervix, and in other cases it was observed only in the advanced stage of tumor such as chromosomes 4 and 16q loss in hepatocellular carcinoma. These results suggest that there are two different types of tumor-suppressor genes: one is the gene whose inactivation is responsible for malignant transformation of a normal cell and the other is the gene whose inactivation is responsible for the progression of a tumor cell. In SCLC, LOH at three different chromosomal loci, 3p, 13q, and 17p, was simultaneously observed in nearly 100% of tumors. It was observed even in stage I tumors and an untreated tumor, and it occurred prior to N-myc amplification. These results may imply that at least six genetic alterations are necessary to convert a normal cell into a fully malignant cancer cell in SCLC.
O02: Doxycycline in the management of bullous pemphigoid: real‐world data from a specialist centre
Authors: S Mahil, M Yates, Z Yiu, S Langan, T Tsakok, N Dand, K Mason, H Mcateer, F Meynell, B Coker, A Vincent, D Urmston, A Vesty, J Kelly, C Lancelot, L Moorhead, H Bachelez, F Capon, C Contreras, C De, La Cruz, P Meglio, P Gisondi, D Jullien, J Lambert, L Naldi, S Norton, L Puig, P Spuls, T Torres, R Warren, H Waweru, J Weinman, C Griffiths, J Barker, M Brown, J Galloway, C Smith, A Ji-Xu, D Lei, K Nguyen, J Yang, M Erickson, K Cheng, S Worswick, N Maloney
Journal: British Journal of Dermatology (2021)

Numerous IMSDs have been described in the context of HIV/ AIDS in case series and reports.However, population-level data evaluating the association of IMSD with HIV/AIDS remains scarce, with no large-scale studies investigating this question.Thus, we investigated the prevalence and
SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
Authors: Sacha Rothschild, Alfred Zippelius, Spasenija Savic, Michel Gonzalez, Walter Weder, Alexandros Xyrafas, Corinne Rusterholz, Miklos Pless
Journal: Journal of Clinical Oncology (2016)

TPS8573 Background: Improving the outcome of locally advanced non-small cell lung cancer (NSCLC) is one of the major challenges in thoracic oncology. SAKK substantially contributed to establish a standard of care for patients with stage III NSCLC: The trial SAKK 16/96 established neoadjuvant chemotherapy with three cycles of cisplatin and docetaxel. The randomized trial SAKK 16/00 showed no benefit by adding radiotherapy as third treatment modality to chemotherapy and surgery. Our results consistently showed a 5-year overall survival (OS) of 37%. However, it seems very difficult to further improve the OS by conventional therapies. Methods: This is a single-arm phase II clinical trial designed to evaluate the addition of perioperative immunotherapy with the anti-PD-L1 antibody durvalumab to the previously established standard of care for stage IIIA(N2) patients, which is based on the trials SAKK 16/96 and SAKK 16/00. Eligible patients with WHO performance status 0-1 and age of 18-75 years must have pathologically proven NSCLC stage IIIA(N2) (T1-3 N2 M0) according to the 7th edition of the TNM classification, irrespective of histological subtype, genomic aberrations or PD-L1 expression status. Tumor tissue has to be available for the mandatory translational research. Patients whose tumor is deemed resectable at diagnosis receive three cycles of chemotherapy with cisplatin 100 mg/m2 and docetaxel 85 mg/m2 every three weeks followed by two cycles of durvalumab 750 mg every two weeks. Following surgery, patients will be treated with durvalumab 750 mg every two weeks for 12 months. Patients with R1/R2 resection and patients with extracapsular spread of mediastinal lymph node metastases may undergo standard radiotherapy prior to adjuvant treatment with durvalumab. The primary endpoint of the trial is event-free survival at 12 months. Secondary endpoints include OS, objective response, nodal down-staging, complete resection, pattern of recurrence and toxicity. Additionally, a large translation research program accompanies the trial investigating potential predictive biomarkers of anti-PD-L1 therapy. Clinical trial information: SNCTP000001480.